68Ga DOTATATE PET/CT Imaging of Elastofibroma Dorsi

Ishiyama, Mitsutomi; Vesselle, Hubert

doi:10.1097/rlu.0000000000002023

Cited by 7 publications

(6 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To our knowledge, there is no study histopathologically investigating SSTR expression in ED. According to our knowledge, following the case report by Ishiyama et al (21), this is the second case showing STTR expression with Ga-68 DOTATATE PET/CT in ED.…”

Section: Discussionsupporting

confidence: 58%

See 1 more Smart Citation

Elastofibroma Dorsi: Positron Emission Tomography/Computed Tomography Perspective

Aksoy¹

2019

Istanbul Med J

View full text Add to dashboard Cite

Amaç: Elastofibroma dorsi (ED), nadir görülen ve yavaş büyüyen bir bağ dokusu tümörü olup, sıklıkla yaşlı hastalarda subskapüler bölgede gözlenmektedir. Bilgisayarlı tomografi (BT), manyetik rezonans görüntüleme, ultrasonografi ve pozitron emisyon tomografi (PET) gibi çeşitli görüntüleme yöntemleri ile tanı konulabilmektedir. Bu retrospektif çalışmada malign veya malign olmayan sebeplerden ötürü uygulanan PET/BT incelemelerinde saptanan ED'lerin klinik özellikleri değerlendiriliştir.Yöntemler: Bu çalışmada Mayıs 2014-Aralık 2017 tarihleri arasında tek bir merkezde onkolojik veya onkolojik olmayan hastalıklar nedeniyle gerçekleştirilen PET/BT incelemeleri retrospektif olarak değerlendirilmiştir. Lezyonların anatomik boyutları BT incelemelerindeki aksiyel kesitler üzerinden değerlendirilmiştir. Lezyonların metabolik aktiviteleri veya reseptör ekspresyon durumları PET incelemesinde saptanan lezyonlar üzerine çizilen ilgi alanlarından elde edilen SUV max değerleri ile hesaplanmıştır.Bulgular: Toplamda 7300 PET raporu "ED" açısından taranmış ve ED saptanan hastaların görüntüleri tekrar değerlendirilmiştir. Yüz otuz bir hastaya ait 174 incelemede (97 kadın, 34 erkek, ortalama yaş: 62.13±8.6) ED saptandı. Prevelans %1,79 olarak saptandı. Yüz on altı hastada (%88,5) bilateral olarak ED saptanmış iken; sağda daha sık olmak üzere 15 hastada tek taraflı (%11,5) ED saptandı. Ortalama çap 2,6x4,9±1,1x1,9cm; ortalama SUV max değeri ise 2,46±0,74 olarak hesaplandı. SUV max değerleri ile ölçülen boyutlar arasında istatistiksel olarak anlamlı farklılık (p=0,001) saptandı.

show abstract

Section: Discussionsupporting

confidence: 58%

“…Various studies showed uptake of different radiopharmaceuticals in ED, other than F-18 FDG; such as I-131, F-18 PSMA and Ga-68 DOTATATE, which is a SSTR agonist (18)(19)(20)(21). In our study, all procedures, except one, were performed with F-18 FDG.…”

Section: Discussionmentioning

confidence: 76%

Elastofibroma Dorsi: Positron Emission Tomography/Computed Tomography Perspective

Aksoy¹

2019

Istanbul Med J

View full text Add to dashboard Cite

show abstract

“…Two cases proved to be malignant (29%), including retiform hemangioendothelioma in soft tissue and a non-Hodgkins lymphoma in a lymph node [15,27]. The remaining five benign cases revealed a pleomorphic adenoma in the parotid gland, parathyroid adenoma in close relation to the thyroid gland, elastofibroma dorsi in soft tissue, a uterine leiomyoma, and fibrous dysplasia in the femoral bone [8,[28][29][30][31].…”

Section: Miscellaneousmentioning

confidence: 99%

Prevalence and significance of incidental findings on 68 Ga-DOTA-conjugated somatostatin receptor-targeting peptide PET/CT: a systematic review of the literature

2022

View full text Add to dashboard Cite

Aim We aimed to evaluate the prevalence of incidental 68 Ga-DOTA-conjugated somatostatin receptor-targeting peptide PET/CT (SSTR PET/CT) findings, their clinical significance in the need for follow-up, and their risk of malignancy. Materials and methods Studies reporting incidental SSTR PET/CT findings were systematically searched in PubMed, Cochrane, Embase and Web of Science literature published prior to 1st of May 2020. Studies were filtered by two independent readers for eligibility based on title and abstract, and subsequently on full text. The main exclusion criteria were: 1) pathological findings that matched scan indication, 2) known organ specific disease and/or incidental findings confirmed on other scan modality prior to SSTR PET/CT, 3) lack of diagnosis and/or follow up, and 4) results published in proceedings or conference abstracts. Results Twenty-one studies, comprising a total of 2906 subjects, were eligible for the analysis. Studies included were retrospective cohort studies on incidental SSTR PET/CT findings in a specific organ (n = 2888, 7/21) or case reports (n = 18, 14/21). A total of 133 subjects had incidental SSTR PET/CT findings. Incidental findings were predominantly seen in the thyroid gland (n = 65), spine (n = 30), brain (n = 26) and breast (n = 6). Seventeen of 133 (13%) incidental findings were malignant on final diagnosis. Incidental breast findings were associated with the highest risk of malignancy (67%). In the thyroid, incidental SSTR uptake was caused by malignancy in 8%, all presenting as focal uptake. The lowest risk was seen in the spine with a malignancy rate of 3% in patients with incidental SSTR uptake and benign cases were interpreted as vertebral hemangiomas on CT. Incidental SSTR PET/CT findings in other locations were of malignant etiology in two out of six cases (33%) and should be evaluated individually. Conclusion The most incidental SSTR PET/CT findings were found in the thyroid gland, spine, and brain. The risk of malignancy was greatest in incidental SSTR PET/CT findings in the breast, cranially, and thyroid gland. The results of the present study can prove useful in the interpretation of atypical findings on SSTR PET/CT and in the counseling of clinicians.

show abstract

“…Although the 68 Ga-DOTATATE PET/CT scans are highly sensitive and specific in detecting NETs, false-positive uptake may lead to diagnostic challenges 3–6 . 68 Ga-DOTATATE uptake has been frequently reported in various nonendocrine tumors and lesions resulting in interpretative errors 7–10 . According to Kagna et al, 11 the 68 Ga-DOTA-NOC uptake was not associated with any NET in 72% of cases, and the uterus was the third most common location of tracer accumulation.…”

mentioning

confidence: 99%

False-Positive 68Ga-DOTATATE Uptake in a Uterine Subserosal Fibroid Mimicking Mesenteric Neuroendocrine Tumor

Khalaj¹,

Rowe

Thupili³

et al. 2023

Clin Nucl Med

View full text Add to dashboard Cite

68Ga-DOTATATE PET/CT is a highly sensitive and specific imaging modality in detecting neuroendocrine tumors. False-positive DOTATATE uptake poses diagnostic challenges. False-positive uptake in a uterine fibroid is the third most common location. We report the case of a 45-year-old woman with clinical concern for possible neuroendocrine tumor showing moderate focal DOTATATE uptake, which was initially thought of to be localized to mesentery on PET/CT images but was subsequently localized to a subserosal uterine fibroid following MRI. Patient underwent hysterectomy, further confirming that the uterine myometrial uptake is within the subserosal fibroid.

show abstract

68Ga DOTATATE PET/CT Imaging of Elastofibroma Dorsi

Cited by 7 publications

References 8 publications

Elastofibroma Dorsi: Positron Emission Tomography/Computed Tomography Perspective

Elastofibroma Dorsi: Positron Emission Tomography/Computed Tomography Perspective

Prevalence and significance of incidental findings on 68 Ga-DOTA-conjugated somatostatin receptor-targeting peptide PET/CT: a systematic review of the literature

False-Positive 68Ga-DOTATATE Uptake in a Uterine Subserosal Fibroid Mimicking Mesenteric Neuroendocrine Tumor

Contact Info

Product

Resources

About